Integrate multiple modes of biology from a single sample in a single experiment to provide transformative insights into health and disease.
Read the latest research paper featuring 6-base sequencing in Nature Structural & Molecular Biology.
Current technologies are unable to reliably resolve both genetic and epigenetic sequences at low sample input and miss important information. biomodal’s duet multiomics solution evoC gives you access to the 6-base genome – all four canonical bases and distinguishes 5‑methylcytosine (5mC) and 5‑hydroxymethylcytosine (5hmC) – from a single 5ng DNA sample, in a single experiment, with high accuracy.
Combined epigenetic and genetic analysis in a single sequencing run lets you access the most critical information from your DNA samples.
Better characterise liquid biopsy and genomic DNA samples of early stage cancer for diagnostic and therapy development.
Combined data reveals the role of methylation in neurodegeneration.
Pinpoint epigenetic changes that determine patterns of disease and health throughout a lifespan.
Improved DNA-based diagnostics with the ability to see disease-relevant changes from low input samples
Detect minute epigenetic changes to better understand maternal and foetal health.
A true 6-base genome that distinguishes 5mC and 5hmC together with all four canonical bases to measure multiple modes of biology
Assess all four canonical bases plus modified cytosine
Download this poster Credits William Stark Mark Hill Jack Monahan Jean Teyssandier Chenfu Shi Nicola Wong Hugo Sepulvega Isaac Lopez-Moyado Nicholas Harding Anjana Rao Paidi
The combination of PARPi (Talazoparib – TAL) and DNMTi (Decitabine – DAC) functions synergistically to inhibit PCa cell lines and patient-derived PTOs.
Circulating tumor DNA (ctDNA) purity can be used to predict therapy response of metastatic castration-resistant prostate cancer (mCRPC) to PD-L1/PARP1 inhibition.
We can help you reveal new data and multimodal insights from your research.
